Rocket Pharmaceuticals sold its rare disease pediatric priority review voucher for $180 million, cash that the company will use to support a pipeline now led by a gene therapy in

Healthcare has made real progress on interoperability, but we are still solving the wrong problem. We have APIs, standards, and more data moving between systems than ever before, yet the

Healthcare environments are designed for efficiency, safety, and flow. Hallways are sized for beds, nurse stations are positioned for visibility, and rooms are built around equipment. That system works for

Approximately two million new cancer cases are diagnosed in the United States each year. One of the most important aspects of cancer care for many patients won’t be a breakthrough

Amgen is standing behind a rare disease drug that the FDA wants off the market due to safety concerns and alleged clinical trial manipulation, and its defense will include a

A new report from the Office of Inspector General revealed that the three largest Medicare Advantage insurers denied prior authorization requests for long-term acute care and inpatient rehabilitation at high

Healthcare is in the middle of an AI gold rush, with investors, providers and payers pouring more money than ever before into new technology. But according to a group of

Apparently, it’s not just me. I’m probably like most buyers of products or services, especially those in high tech. Watching a video of some other person using or demonstrating a

Clinical AI startup Abridge is one of the most well-funded health tech startups in the nation, having raised $1.1 billion since its founding in 2018. On Thursday, the startup held

A Novartis RNA therapy reduced blood levels of a protein that’s a biological indicator of a particular form of muscular dystrophy, clinical trial results that could support an application seeking